JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 4, 2006; DOI: 10.1124/jpet.106.111674

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.111674v1
321/1/1    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ito, K.
Right arrow Articles by Adcock, I. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ito, K.
Right arrow Articles by Adcock, I. M


Received for publication July 28, 2006.
Revised October 1, 2006.
Accepted for publication October 2, 2006.

Therapeutic potential of PI3K inhibitors in inflammatory respiratory disease

Kazuhiro Ito 1*, Gaetano Caramori 2, Ian M Adcock 3

1 NHLI, Imperial College 2 Centro di Ricerca su Asma e BPCO, Universita di Ferrara, Italy 3 Airway Disease, NHLI, Imperial College

* Address correspondence to: E-mail: k.ito{at}imperial.ac.uk

Abstract

The phosphoinositide 3-kinases (PI3Ks) are a family of proteins that catalyze the phosphorylation of the 3-OH position of phosphoinositides and generate lipids that control a wide variety of intracellular signalling pathways. They are classified into three families according to their structure and substrate specificity and are thought to have distinct biological roles. Recent studies suggested that numerous components of the PI3K pathway play a crucial role in the expression and activation of inflammatory mediators, inflammatory cell recruitment, immune cell function and airway remodelling as well as corticosteroid insensitivity in chronic inflammatory respiratory disease. Selective PI3K inhibitors have been developed which reduce inflammation and some characteristics of disease in experimental animal models. Targeting specific PI3K isoforms that may be overexpressed or overactive in disease, should allow for selective treatment of respiratory diseases. Encouraging data from animal models, primary cells and clinical studies in other diseases suggest that inhibitors of PI3K/Akt may prove to be useful novel therapies in the treatment of asthma and COPD.


Key words: COPD, PI3K, airway, asthma, inflammation, inhibitor


This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
A. Webb, A. Johnson, M. Fortunato, A. Platt, T. Crabbe, M. I. Christie, G. F. Watt, S. G. Ward, and L. A. Jopling
Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists
J. Leukoc. Biol., October 1, 2008; 84(4): 1202 - 1212.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Respiratory DiseaseHome page
M. Baroffio, E. Crimi, and V. Brusasco
Review: Airway smooth muscle as a model for new investigative drugs in asthma
Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 129 - 139.
[Abstract] [PDF]

Home page
 Mol. Pharmacol.Home page
H. S. M. Farghaly, I. S. Blagbrough, D. A. Medina-Tato, and M. L. Watson
Interleukin 13 Increases Contractility of Murine Tracheal Smooth Muscle by a Phosphoinositide 3-kinase p110{delta}-Dependent Mechanism
Mol. Pharmacol., May 1, 2008; 73(5): 1530 - 1537.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.